Bioject to Report Fiscal 2003 First-Quarter Results on July 25, 2002.Business Editors Bioject Medical Technologies Inc., (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, announced today that the Company will report its fiscal 2003 first-quarter financial results on Thursday, July 25, 2002 at 7:30 a.m. Eastern Daylight Time, and hold a conference call at 10:00 a.m. Eastern Daylight Time. To participate in the call via telephone, please dial 800/388-8975, or to hear the call live over the Internet Internet Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the , visit www.bioject.com. A conference call replay will be available until August 1, 2002. To listen to the replay, please dial 800/428-6051, replay pass code 252921. Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with manufacturing facilities in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice orifice /or·i·fice/ (or´i-fis) 1. the entrance or outlet of any body cavity. 2. any opening or meatus.orific´ial aortic orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating penetrating breaching the tissues of the body. the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial Adj. 1. mutually beneficial - mutually dependent interdependent, mutualist dependent - relying on or requiring a person or thing for support, supply, or what is needed; "dependent children"; "dependent on moisture" agreements with leading pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . Bioject's strategic partners include Serono and Alkermes. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Forms 10-K and Forms 10-Q for further discussions of factors that could affect future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change. For more information about Bioject, visit: www.bioject.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion